Daniel G. Welch
Mr. Welch has spent his career of forty years in the business of developing medicines in both biotech and multi-national pharmaceutical companies. He has had an executive leadership or board director role in developing and/or commercializing over a dozen breakthrough medicines for patients with HIV, multiple sclerosis, cardiovascular disease, cancer and several rare diseases.
Mr. Welch served in several leadership positions, among them: various roles at Sanofi, a leading multinational company, including VP of Global Marketing in Paris and COO of the US business; President of Elan Pharmaceuticals; CEO and Chairman of Triangle Pharmaceuticals acquired by Gilead; CEO and Chairman of InterMune, acquired by Roche and Chairman of Avexis, acquired by Novartis Mr. Welch currently serves as the Chairman of the Board or board director of several public and private biotech companies that are developing medicines and gene therapies to treat various forms of cancer, orphan diseases and diseases of the cardiovascular and metabolic system. He is also an advisor to biotech CEOs.
Mr. Welch holds a B.A. degree with honors from the University of Miami and M.B.A. degree from the University of North Carolina. He has published a novel, Race for the Mind in which the main characters are biotech CEOs.